Opiods and MAT Flashcards

1
Q

When need to check MassPat

A

required to check EVERY time a schedule II or III narcotic or a benzodiazepine are prescribed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Whether risk of opioid overdose is higher or lower with extended-release opioids

A

Risk of OD higher with extended release opioids, immediate release should be used when beginning treatment, there is no evidence that extended release are more effective

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Delta:

A

Diffusely found in the brain and spinal cord
◦ Weaker analgesic effect but also fewer side effects such as respiratory depression
◦ Can have some mood related effects including dysphoria, delusions, hallucinations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

kappa

A

Dorsal horn of spinal cord and brain stem ◦ Analgesia, miosis, sedation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Mu

A

main target
◦Located at supraspinal and spinal sites and the gut
◦ Analgesia and respiratory depression
◦ Mioisis (oculomotor nerve), euphoria, reduced g.i. motility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Schedule I

A

heroin & marijuana

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

shedule II

A

Oxycodone – mu, kappa, delta receptors
Hydrocodone- mu
Fentanyl- mu receptor
Methadone – mu receptor
Adderall

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Schedule III

A

Codeine (Scheduled III or V depending on dose) - mu selective

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

schedule IV

A

Tramadol – mu receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How to calculate MMEs

A

1). determine total daily amount of each opioid the patient takes
2). Convert each to MMEs-multiply the dose for each opioid by the conversion factor (see table)
3). Add them together

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Recommendations for tapering opioids

A

◦ Consider tapering if:
◦ No meaningful improvement in pain and function
◦ Doses > 50 MME/day
◦ Signs of substance use disorder
◦ Overdose/serious adverse effects
◦ How to taper
◦ Goal: minimize withdrawal symptoms
◦ If on opioids >1 year – decrease by 10% per month
◦ If <1 year could consider decrease by 10% per week
◦ Monitor patient’s response and adjust accordingly
◦ Optimize non-opioid pain management and psychosocial support
◦ Discuss risk for overdose if abrupt return to higher dosages
◦ Monitor for signs of depression, anxiety and opioid use disorder

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What naltrexone does

A

Opiod antagonist meaning it binds to opioid receptors but doesn’t activate them. This prevents other opioids from producing a high
Reduces cravings and helps prevent relapse after detox
Can precipitate withdrawal if taken too soon after opioid use so person must be opioid free for 7-10 days before starting it

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Which drugs used to treat substance abuse disorder have the greatest risk for overdose

A

Methadone due to long/ variable half life

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which medication is an opioid antagonist

A

naltrexone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

When start naltrexone how long should patient be opioid free before you initiate treatment

A

recommends that patients be
opioid-free followed by a wait-period
of 7-10 days before treatment can be
initiated, to avoid precipitated withdrawal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Buprenorphine bioavailability percent after the significant first pass metabolism what that results in the oral bioavailability of that drug (percentage)

A

Oral bioavailability<5%